| Mr Carlos Nicolas Prieto Granada, MD | |
|
3601 The Vanderbilt Clinic, Nashville, TN 37232-4742 | |
| (615) 322-3000 | |
| Not Available |
| Full Name | Mr Carlos Nicolas Prieto Granada |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 22 Years |
| Location | 3601 The Vanderbilt Clinic, Nashville, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083857791 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Vanderbilt University Medical Center | Nashville, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Vanderbilt University Medical Center | 5092023416 | 2711 |
News Archive
Ryan & Maniskas, LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by members of the Board of Directors of BioSphere Medical, Inc. in connection with their actions in causing BioSphere Medical to enter into a merger agreement with Merit Medical System, Inc. and Merit BioAcquisition Co., a wholly-owned subsidiary of Merit Medical pursuant to which BioSphere Medical will merge with and into Merit BioAcquisition Co.
Researchers have identified new molecules that kill cancer cells while protecting healthy cells and that could be used to treat a variety of different cancers. The research shines a light on what happens to cells at the moment they become cancerous.
The existing prognostic scores for early-risk stroke prediction after transient ischaemic attack (TIA have been validated and refined to develop a unified score that is more predictive than previous methods, according to an Article published in this week's issue of The Lancet.
Exelixis, Inc. today announced it has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma who have experienced disease progression following treatment with at least one prior VEGFR tyrosine kinase inhibitor.
In the wake of the COVID-19 pandemic, the U.S. Centers for Disease Control and Prevention recommends that people wear masks in public.
› Verified 7 days ago
| Entity Name | Vanderbilt University Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104202761 PECOS PAC ID: 5092023416 Enrollment ID: O20151006000369 |
News Archive
Ryan & Maniskas, LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by members of the Board of Directors of BioSphere Medical, Inc. in connection with their actions in causing BioSphere Medical to enter into a merger agreement with Merit Medical System, Inc. and Merit BioAcquisition Co., a wholly-owned subsidiary of Merit Medical pursuant to which BioSphere Medical will merge with and into Merit BioAcquisition Co.
Researchers have identified new molecules that kill cancer cells while protecting healthy cells and that could be used to treat a variety of different cancers. The research shines a light on what happens to cells at the moment they become cancerous.
The existing prognostic scores for early-risk stroke prediction after transient ischaemic attack (TIA have been validated and refined to develop a unified score that is more predictive than previous methods, according to an Article published in this week's issue of The Lancet.
Exelixis, Inc. today announced it has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma who have experienced disease progression following treatment with at least one prior VEGFR tyrosine kinase inhibitor.
In the wake of the COVID-19 pandemic, the U.S. Centers for Disease Control and Prevention recommends that people wear masks in public.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Carlos Nicolas Prieto Granada, MD 3841 Green Hills Village Dr Ste 200, Nashville, TN 37215-2691 Ph: () - | Mr Carlos Nicolas Prieto Granada, MD 3601 The Vanderbilt Clinic, Nashville, TN 37232-4742 Ph: (615) 322-3000 |
News Archive
Ryan & Maniskas, LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by members of the Board of Directors of BioSphere Medical, Inc. in connection with their actions in causing BioSphere Medical to enter into a merger agreement with Merit Medical System, Inc. and Merit BioAcquisition Co., a wholly-owned subsidiary of Merit Medical pursuant to which BioSphere Medical will merge with and into Merit BioAcquisition Co.
Researchers have identified new molecules that kill cancer cells while protecting healthy cells and that could be used to treat a variety of different cancers. The research shines a light on what happens to cells at the moment they become cancerous.
The existing prognostic scores for early-risk stroke prediction after transient ischaemic attack (TIA have been validated and refined to develop a unified score that is more predictive than previous methods, according to an Article published in this week's issue of The Lancet.
Exelixis, Inc. today announced it has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma who have experienced disease progression following treatment with at least one prior VEGFR tyrosine kinase inhibitor.
In the wake of the COVID-19 pandemic, the U.S. Centers for Disease Control and Prevention recommends that people wear masks in public.
› Verified 7 days ago
Dr. Digna Saunders Forbes, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 1005 Dr. D. B. Todd Blvd, Nashville, TN 37208 Phone: 615-327-6438 Fax: 615-327-5634 | |
Mary Ann Arildsen, MD, PHD Pathology Medicare: Accepting Medicare Assignments Practice Location: 3601 Tvc, Nashville, TN 37232 Phone: 615-322-3000 | |
Eszter Szentirmai, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-322-3000 | |
Dr. Henry Douglas Edwards, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 2010 Church St, Ste 615, Nashville, TN 37203 Phone: 615-284-7950 Fax: 615-284-5750 | |
Dr. Robert Eugene Burnette, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 1005 Dr. D. B. Todd Blvd, Nashville, TN 37208 Phone: 615-327-6212 Fax: 615-327-6409 | |
James Chappell, MD, PHD Pathology Medicare: Not Enrolled in Medicare Practice Location: 3601 Tvc, Nashville, TN 37232 Phone: 615-322-3000 | |
Dr. Andy Lo, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 2601 Tvc, Nashville, TN 37232 Phone: 615-322-4916 |